Crispr Therapeutics is trading 6.21% up at $56.26, benefiting primarily from strong biotech-sector momentum rather than a new company-specific announcement.
- The XBI biotech ETF is up 3.73% after Moderna reported positive Phase 3 personalized cancer-vaccine results, improving sentiment across biotechnology.
- Crispr Therapeutics’ latest company update was its August 3 earnings release; no newer catalyst was identified in the August 19 search results.